A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Cobicistat (Primary) ; GSK 2838232 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors GlaxoSmithKline
- 10 Jun 2018 Status changed from recruiting to completed.
- 12 Mar 2018 Planned End Date changed from 11 Mar 2018 to 15 Apr 2018.
- 12 Mar 2018 Planned primary completion date changed from 11 Mar 2018 to 15 Apr 2018.